• Cynthia Villarreal-Garza, Enrique Soto-Perez-de-Celis, Erika Sifuentes, Santiago Ruano, Berenice Baez-Revueltas, Fernando Lara-Medina, Claudia Arce-Salinas, Alberto Alvarado-Miranda, Yanin Chavarri-Guerra, Claudia Caro-Sanchez, Noel Castañeda-Soto, Enrique Bargallo-Rocha, and Alejandro Mohar.
• Department of Medical Oncology, National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico; Unit of Biomedical Investigation in Cancer, National Autonomous University of Mexico and National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico; Breast Cancer Center, Instituto Tecnológico de Monterrey, Eugenio Garza Sada Sur 2501, Tecnológico, 64849 Monterrey, NL, Mexico. Electronic address: cynthiavg@gmail.com.
• Breast. 2015 Jun 1; 24 (3): 218-23.

IntroductionEvidence regarding the outcomes of Hispanic women with breast cancer is lacking. We analyzed women with HER2+ disease treated with trastuzumab-based neoadjuvant chemotherapy in Mexico.Methods244 patients were included. Outcomes were compared between patients who achieved pathologic complete response (pCR) (n = 119), or less than pCR (n = 125). Patients with noninvasive (ypT0/is, ypN0) residual disease were also analyzed.Results119 (48.8%) patients achieved pCR. pCR was the only factor associated with improved 3 year survival (98.1% vs 92.3%: P = 0.02). Survival was better in patients with ypT0/is, ypN0 response than in those with residual invasive disease (p < 0.01). 3 year survival was 98.1% for patients with pCR and 92.6% for patients with ypTis, ypN0 response (p = 0.64).ConclusionsResponse rates to trastuzumab based neoadjuvant chemotherapy in Hispanics mimic that of other ethnic groups. This underlines the fact that access to treatment, rather than ethnicity, is the main prognostic factor in this population.Copyright © 2015 Elsevier Ltd. All rights reserved.

36 keywords...

hide…